

Anders Jakobsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8191240/publications.pdf>

Version: 2024-02-01

124
papers

5,037
citations

126907

33
h-index

102487

66
g-index

125
all docs

125
docs citations

125
times ranked

7477
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. <i>Lancet, The</i> , 2018, 391, 2537-2545.	13.7	677
2	Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 419-423.	2.5	500
3	High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. <i>Lancet Oncology, The</i> , 2015, 16, 919-927.	10.7	435
4	Quantitative Cell-Free DNA, <i>KRAS</i> , and <i>BRAF</i> Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. <i>Clinical Cancer Research</i> , 2012, 18, 1177-1185.	7.0	244
5	Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology, The</i> , 2021, 22, 43-50.	10.7	122
6	Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0108247.	2.5	109
7	The prognostic value of <i>KRAS</i> mutated plasma DNA in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 312-317.	2.0	101
8	Granulosa Cell Tumor of the Ovary: A Population-Based Study of 37 Women with Stage I Disease. <i>Gynecologic Oncology</i> , 2001, 81, 456-460.	1.4	100
9	Dose-Effect Relationship in Chemoradiotherapy for Locally Advanced Rectal Cancer: A Randomized Trial Comparing Two Radiation Doses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 949-954.	0.8	100
10	Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2984-2991.	5.1	94
11	Neoadjuvant chemotherapy in locally advanced colon cancer. <i>A phase II trial</i> . <i>Acta Oncologica</i> , 2015, 54, 1747-1753.	1.8	84
12	PET/CT and Histopathologic Response to Preoperative Chemoradiation Therapy in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 21-25.	1.3	77
13	Changes in mutational status during third-line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, <i>KRAS</i> and <i>BRAF</i> in the plasma. <i>International Journal of Cancer</i> , 2014, 135, 2215-2222.	5.1	76
14	Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer. <i>Journal of Oncology</i> , 2011, 2011, 1-12.	1.3	74
15	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017, 22, 1049-1055.	3.7	73
16	The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 820-825.	2.5	68
17	Controls to validate plasma samples for cell free DNA quantification. <i>Clinica Chimica Acta</i> , 2015, 446, 141-146.	1.1	63
18	Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 461-465.	0.8	60

#	ARTICLE	IF	CITATIONS
19	The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2012, 12, 83.	2.6	51
20	Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , 2014, 50, 2611-2618.	2.8	50
21	The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 715-720.	2.2	49
22	Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e96767.	2.5	49
23	Anal carcinoma " Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. <i>Radiotherapy and Oncology</i> , 2014, 113, 352-358.	0.6	49
24	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685.	2.8	48
25	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019, 141, 392-396.	7.1	47
26	Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 110-118.	0.8	46
27	Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1040-1047.	2.5	44
28	Selection of colon cancer patients for neoadjuvant chemotherapy by preoperative CT scan. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 202-208.	1.5	44
29	Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 251-260.	2.8	42
30	Screening for circulating RAS/RAF mutations by multiplex digital PCR. <i>Clinica Chimica Acta</i> , 2016, 458, 138-143.	1.1	37
31	Germline Polymorphisms may Act as Predictors of Response to Preoperative Chemoradiation in Locally Advanced T3 Rectal Tumors. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1363-1369.	1.3	36
32	Tumor"stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. <i>Acta Oncol"gica</i> , 2018, 57, 528-533.	1.8	36
33	Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. <i>Acta Oncol"gica</i> , 2007, 46, 1113-1117.	1.8	34
34	Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 155-161.	1.1	34
35	Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. <i>Oncology Reports</i> , 2014, 31, 969-974.	2.6	34
36	Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. <i>Clinica Chimica Acta</i> , 2015, 439, 97-101.	1.1	33

#	ARTICLE	IF	CITATIONS
37	Veliparib Monotherapy to Patients With <i>BRCA</i> Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1842-1849.	2.5	33
38	Improved Classification of Epithelial Ovarian Cancer: Results of 3 Danish Cohorts. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1592-1600.	2.5	32
39	MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0150593.	2.5	32
40	Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in <i>BRCA</i> -mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2020, 125, 121-129.	2.8	32
41	Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 556-563.	0.8	32
42	Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 440-446.	1.5	31
43	Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. <i>British Journal of Cancer</i> , 2018, 119, 1367-1373.	6.4	30
44	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , 2012, 5, 23.	3.0	29
45	The Prognostic Value of <i>BRCA1</i> and PARP Expression in Epithelial Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 180-189.	1.4	28
46	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , 2020, 59, 652-659.	1.8	28
47	Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 578-584.	2.5	27
48	Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3278-3282.	7.0	26
49	Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091847.	3.2	26
50	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , 2014, 44, 1736-1744.	3.3	25
51	Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. <i>Acta Oncologica</i> , 2015, 54, 179-186.	1.8	25
52	A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial. <i>International Journal of Colorectal Disease</i> , 2008, 23, 251-255.	2.2	24
53	The importance of $\text{rs}1460$ C/T and $\text{rs}405$ G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 751-758.	2.5	24
54	Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. <i>Pharmacogenomics</i> , 2011, 12, 1681-1693.	1.3	24

#	ARTICLE	IF	CITATIONS
55	Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. <i>Oncology Letters</i> , 2011, 2, 1101-1106.	1.8	24
56	The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1474-1482.	2.5	23
57	Transrectal ultrasound and magnetic resonance imaging measurement of extramural tumor spread in rectal cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 5021.	3.3	21
58	Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 73-80.	2.5	21
59	Quantification of NK cell activity using whole blood: Methodological aspects of a new test. <i>Journal of Immunological Methods</i> , 2018, 458, 21-25.	1.4	20
60	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021, 149, 128-133.	2.8	20
61	EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 107.	2.6	19
62	The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1390-1398.	2.5	19
63	Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. <i>Oncology Letters</i> , 2017, 14, 201-209.	1.8	19
64	Report of an Early Stopped Randomized Trial Comparing Cisplatin vs. Cisplatin/Ifosfamide/5-Fluorouracil in Recurrent Cervical Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2005, 59, 126-129.	1.6	18
65	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. <i>Scientific Reports</i> , 2017, 7, 2388.	3.3	18
66	A Phase II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. <i>Acta Oncologica</i> , 2011, 50, 448-454.	1.8	17
67	Epidermal Growth Factor-like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2238-2245.	4.1	17
68	The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 254.	4.4	17
69	NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1649.	3.7	17
70	The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 166-173.	2.5	17
71	Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. <i>Pharmacogenomics</i> , 2012, 13, 763-770.	1.3	16
72	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 7-12.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. PLoS ONE, 2016, 11, e0156919.	2.5	16
74	Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study. Journal of Translational Medicine, 2015, 13, 10.	4.4	15
75	The prognostic value of simultaneous tumor and serum <sc>RAS</sc>/<sc>RAF</sc> mutations in localized colon cancer. Cancer Medicine, 2017, 6, 928-936.	2.8	15
76	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. Translational Oncology, 2019, 12, 968-972.	3.7	15
77	Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 9-13.	1.3	15
78	Visualising and quantifying angiogenesis in metastatic colorectal cancer. Cellular Oncology (Dordrecht), 2013, 36, 341-350.	4.4	14
79	Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncology Letters, 2016, 11, 3967-3974.	1.8	13
80	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. Journal of Ovarian Research, 2020, 13, 59.	3.0	13
81	Performance of the EarlyCDTâ® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort. Lung Cancer, 2021, 158, 85-90.	2.0	13
82	Microsatellite Instability and the Association with Plasma Homocysteine and Thymidylate Synthase in Colorectal Cancer. Cancer Investigation, 2008, 26, 583-589.	1.3	12
83	Protein kinase C-beta II (PKC-Î²II) expression in patients with colorectal cancer. International Journal of Colorectal Disease, 2009, 24, 641-645.	2.2	11
84	A Phase II Trial of Ifosfamide, 5-Fluorouracil, and Leucovorin in Recurrent Uterine Cervical Cancer. Gynecologic Oncology, 1994, 55, 123-125.	1.4	10
85	Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. Expert Review of Anticancer Therapy, 2011, 11, 589-600.	2.4	10
86	Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up. Pathology Research International, 2012, 2012, 1-8.	1.4	10
87	Immunohistological expression of <sc>HIF</sc>â€¹±, <sc>GLUT</sc>â€¹, <sc>B</sc>clâ€² and <sc>K</sc>iâ€¶67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer. Apmis, 2013, 121, 127-138.	2.0	10
88	The Influence of Tissue Ischemia on Biomarker Expression in Colorectal Cancer. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 298-307.	1.2	10
89	Elastography and diffusion-weighted MRI in patients with rectal cancer. British Journal of Radiology, 2015, 88, 20150294.	2.2	10
90	The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer. Cancers, 2010, 2, 1405-1418.	3.7	9

#	ARTICLE	IF	CITATIONS
91	Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment. <i>Clinical Colorectal Cancer</i> , 2019, 18, 28-33.e3.	2.3	9
92	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. <i>Acta Oncologica</i> , 2020, 59, 1016-1023.	1.8	8
93	Long-term anorectal function in rectal cancer patients treated with chemoradiotherapy and endorectal brachytherapy. <i>Colorectal Disease</i> , 2021, 23, 2311-2319.	1.4	8
94	Analysis of a gene panel for targeted sequencing of colorectal cancer samples. <i>Oncotarget</i> , 2018, 9, 9043-9060.	1.8	8
95	The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. <i>Cancers</i> , 2022, 14, 2252.	3.7	8
96	Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. <i>BMC Cancer</i> , 2010, 10, 185.	2.6	7
97	Single nucleotide polymorphisms in the HIF-1 α gene and chemoradiotherapy of locally advanced rectal cancer. <i>Oncology Letters</i> , 2012, 4, 1056-1060.	1.8	7
98	TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. <i>Tumor Biology</i> , 2015, 36, 4301-4308.	1.8	7
99	Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	7
100	Blood natural killer cells during treatment in recurrent ovarian cancer. <i>Acta Oncologica</i> , 2020, 59, 1365-1373.	1.8	7
101	The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 855-865.	2.8	7
102	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021, 522, 152-157.	1.1	7
103	Reporting on circulating tumor DNA monitoring in metastatic cancer: "From clinical validity to clinical utility. <i>Cancer</i> , 2022, 128, 2052-2057.	4.1	7
104	Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. <i>Cancers</i> , 2020, 12, 3728.	3.7	6
105	Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1766.	3.7	6
106	Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations. <i>Scientific Reports</i> , 2020, 10, 20113.	3.3	5
107	Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 127-134.	0.2	4
108	Less extensive surgery compared to extensive surgery: survival seems similar in young women with adult ovarian granulosa cell tumor. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 177, 61-66.	1.1	4

#	ARTICLE	IF	CITATIONS
109	The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 12-18.	0.2	3
110	Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. <i>Acta Oncologica</i> , 2020, 59, 298-301.	1.8	3
111	Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. <i>Anticancer Research</i> , 2020, 40, 5255-5261.	1.1	3
112	Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anus – A Population-Based Experience from the Danish Anal Cancer Group. <i>Cancers</i> , 2021, 13, 3226.	3.7	3
113	Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer. <i>Cancers</i> , 2021, 13, 4223.	3.7	3
114	Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211089.	1.0	3
115	Limitations of tissue micro array in Duke's B colon cancer. <i>Apmis</i> , 2012, 120, 819-827.	2.0	2
116	Radiation Techniques for Increasing Local Control in the Non-Surgical Management of Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 267-274.	0.5	2
117	Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 751-759.	2.3	2
118	In Reply to Fekete. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 213.	0.8	1
119	Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases – a report from the Danish Anal Cancer Group. <i>Acta Oncologica</i> , 2022, 61, 321-327.	1.8	1
120	Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer – A Systematic Review. <i>Cancers</i> , 2022, 14, 2254.	3.7	1
121	The prognostic importance of thymidylate gene polymorphism in colon cancer stage II. <i>International Journal of Colorectal Disease</i> , 2008, 23, 1267-1267.	2.2	0
122	The Clinical Impact of MicroRNA-21 in Low Rectal Cancer Treated with High-Dose Chemoradiotherapy in the Organ Preserving Setting. <i>Gastrointestinal Disorders</i> , 2020, 2, 378-384.	0.8	0
123	Circulating tumor-specific DNA: a stony road to clinical utility. <i>Biomarkers in Medicine</i> , 2020, 14, 331-333.	1.4	0
124	MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. , 2019, 2, 885-896.		0